Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pafase: Phase II

ICOS reported data from its U.S. Phase II trial in 240 patients with severe sepsis or traumatic injuries at risk for acute respiratory distress syndrome (ARDS). In

Read the full 273 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE